Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography
David J Harman, Stephen D Ryder, Martin W James, Matthew Jelpke, Dominic S Ottey, Emilie A Wilkes, Timothy R Card, Guruprasad P Aithal, Indra Neil Guha, David J Harman, Stephen D Ryder, Martin W James, Matthew Jelpke, Dominic S Ottey, Emilie A Wilkes, Timothy R Card, Guruprasad P Aithal, Indra Neil Guha
Abstract
Objectives: To assess the feasibility of a novel diagnostic algorithm targeting patients with risk factors for chronic liver disease in a community setting.
Design: Prospective cross-sectional study.
Setting: Two primary care practices (adult patient population 10,479) in Nottingham, UK.
Participants: Adult patients (aged 18 years or over) fulfilling one or more selected risk factors for developing chronic liver disease: (1) hazardous alcohol use, (2) type 2 diabetes or (3) persistently elevated alanine aminotransferase (ALT) liver function enzyme with negative serology.
Interventions: A serial biomarker algorithm, using a simple blood-based marker (aspartate aminotransferase:ALT ratio for hazardous alcohol users, BARD score for other risk groups) and subsequently liver stiffness measurement using transient elastography (TE).
Main outcome measures: Diagnosis of clinically significant liver disease (defined as liver stiffness ≥8 kPa); definitive diagnosis of liver cirrhosis.
Results: We identified 920 patients with the defined risk factors of whom 504 patients agreed to undergo investigation. A normal blood biomarker was found in 62 patients (12.3%) who required no further investigation. Subsequently, 378 patients agreed to undergo TE, of whom 98 (26.8% of valid scans) had elevated liver stiffness. Importantly, 71/98 (72.4%) patients with elevated liver stiffness had normal liver enzymes and would be missed by traditional investigation algorithms. We identified 11 new patients with definite cirrhosis, representing a 140% increase in the number of diagnosed cases in this population.
Conclusions: A non-invasive liver investigation algorithm based in a community setting is feasible to implement. Targeting risk factors using a non-invasive biomarker approach identified a substantial number of patients with previously undetected cirrhosis.
Trial registration number: The diagnostic algorithm utilised for this study can be found on clinicaltrials.gov (NCT02037867), and is part of a continuing longitudinal cohort study.
Keywords: GENERAL MEDICINE (see Internal Medicine).
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
References
- Ratib S, Fleming KM, Crooks CJ et al. . 1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study. J Hepatol 2014;60:282–9. 10.1016/j.jhep.2013.09.027
- Donnan PT, McLernon D, Dillon JF et al. . Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess 2009;13:1–134, iii–iv, ix-xi 10.3310/hta13250
- Armstrong MJ, Houlihan DD, Bentham L et al. . Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234–40. 10.1016/j.jhep.2011.03.020
- Bhala N, Aithal G, Ferguson J. How to tackle rising rates of liver disease in the UK. BMJ 2013;346:807. 10.1136/bmj.f807
- Murray CJ, Richards MA, Newton JN et al. . UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 2013;381:997–1020. 10.1016/S0140-6736(13)60355-4
- Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008;28:705–12. 10.1111/j.1478-3231.2008.01691.x
- Nyblom H, Berggren U, Balldin J et al. . High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336–9. 10.1093/alcalc/agh074
- Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int 2007;27:694–9. 10.1111/j.1478-3231.2007.01471.x
- Giannini E, Risso D, Botta F et al. . Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218–24. 10.1001/archinte.163.2.218
- Harrison SA, Oliver D, Arnold HL et al. . Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441–7. 10.1136/gut.2007.146019
- McPherson S, Stewart SF, Henderson E et al. . Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265–9. 10.1136/gut.2010.216077
- McPherson S, Anstee QM, Henderson E et al. . Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013;25:652–8. 10.1097/MEG.0b013e32835d72cf
- Yoneda M, Imajo K, Eguchi Y et al. . Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 2013;48:1051–60.
- Friedrich-Rust M, Ong MF, Martens S et al. . Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960–74. 10.1053/j.gastro.2008.01.034
- Foucher J, Chanteloup E, Vergniol J et al. . Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403–8. 10.1136/gut.2005.069153
- Boursier J, Zarski JP, de Ledinghen V et al. . Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182–91. 10.1002/hep.25993
- Echosens. Fibroscan recommendations—updated recommendations for a reliable Fibroscan liver stiffness measurement 2013.
- Myers RP, Pomier-Layrargues G, Kirsch R et al. . Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199–208. 10.1002/hep.24624
- Roulot D, Costes JL, Buyck JF et al. . Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011;60:977–84. 10.1136/gut.2010.221382
- Prati D, Taioli E, Zanella A et al. . Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10. 10.7326/0003-4819-137-1-200207020-00006
- Wai CT, Greenson JK, Fontana RJ et al. . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
- Vallet-Pichard A, Mallet V, Nalpas B et al. . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6. 10.1002/hep.21669
- McCorry RB, Palaniyappan N, Chivinge A et al. . Development and evaluation of a nurse-led transient elastography service for the staging of hepatic fibrosis in patients with suspected chronic liver disease. QJM 2012;105:749–54. 10.1093/qjmed/hcs043
- Khadjesari Z, Marston L, Petersen I et al. . Alcohol consumption screening of newly-registered patients in primary care: a cross-sectional analysis. Br J Gen Pract 2013;63:e706–12. 10.3399/bjgp13X673720
- Group UKCCSP. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 2004;329:133 10.1136/bmj.38153.491887.7C
- Meissner HI, Breen N, Klabunde CN et al. . Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomark 2006;15:389–94. 10.1158/1055-9965.EPI-05-0678
- Sheron N, Moore M, Ansett S et al. . Developing a ‘traffic light’ test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Br J Gen Pract 2012;62:470–1. 10.3399/bjgp12X654588
- Wong VW, Chu WC, Wong GL et al. . Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–15. 10.1136/gutjnl-2011-300342
- Zelber-Sagi S, Ratziu V, Zvibel I et al. . The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 2012;24:262–9. 10.1097/MEG.0b013e32834f15dd
- Williams CD, Stengel J, Asike MI et al. . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–31. 10.1053/j.gastro.2010.09.038
- Poynard T, Lebray P, Ingiliz P et al. . Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010;10:40 10.1186/1471-230X-10-40
- Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195–9. 10.1016/S0168-8278(01)00094-0
- Mofrad P, Contos MJ, Haque M et al. . Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–92. 10.1053/jhep.2003.50229
- Verma S, Jensen D, Hart J et al. . Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013;33:1398–405. 10.1111/liv.12226
- Fracanzani AL, Valenti L, Bugianesi E et al. . Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792–8. 10.1002/hep.22429
- Bertholet N, Daeppen JB, Wietlisbach V et al. . Reduction of alcohol consumption by brief alcohol intervention in primary care—systematic review and meta-analysis. Arch Intern Med 2005;165: 986–95. 10.1001/archinte.165.9.986
- Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012;56:255–66. 10.1016/j.jhep.2011.06.010
- Fleming MF, Mundt MP, French MT et al. . Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med Care 2000;38:7–18. 10.1097/00005650-200001000-00003
- Fleming MF, Mundt MP, French MT et al. . Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res 2002;26:36–43. 10.1111/j.1530-0277.2002.tb02429.x
- Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008;28:650–8. 10.1111/j.1478-3231.2008.01693.x
- Merkel C, Marin R, Angeli P et al. . A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476–84. 10.1053/j.gastro.2004.05.004
- Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001;33:802–7. 10.1053/jhep.2001.23054
- Thompson Coon J, Rogers G, Hewson P et al. . Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008;98:1166–75. 10.1038/sj.bjc.6604301
- Consortium YHE. An economic evaluation of ultrasound elastography in the diagnosis of liver fibrosis 2012.
Source: PubMed